TNFSF13B and B-cell chronic lymphocytic leukemia: Based on our findings, we conclude that the combined application of belimumab with rituximab/venetoclax for treatment of relapsed/refractory CLL constitutes a promising therapeutic approach to elucidate whether neutralization of BAFF can serve to further improve treatment options of patients.